Pharmacological effects and clinical evaluation of Brivaracetam

Brivaracetam/Brivaracetam is a new generation of anti-epileptic drugs developed by the Belgian company UCB. It is a structural derivative of Levetiracetam, but it is more selective and stable in terms of pharmacological activity, affinity and neural regulation mechanism. This drug was first approved by the US FDA in 2016 for the treatment of partial-onset epilepsy. It is currently one of the central nervous system drugs that is widely used in clinical practice and well tolerated. Its trade names in different countries include Briviact, Brivlera, etc. As a high-affinity synaptic vesicle protein 2A (SV2A) ligand, Brivaracetam exhibits high efficacy and safety by precisely acting on the neurotransmitter release mechanism.

From the perspective of pharmacological mechanism, the main target of brivaracetam is synaptic vesicle proteinSV2A, which is an important protein in the central nervous system that regulates neurotransmitter release. Epileptic seizures are essentially the result of abnormal synchronized discharge of neurons, and functional abnormalities of SV2A are closely related to this discharge. Brivaracetam can selectively bind to SV2A protein and reduce the release of excitatory transmitters such as glutamate, thereby stabilizing neural network activity and inhibiting the discharge of over-excited neurons. This mechanism of action is different from traditional sodium channel or calcium channel blockers, so it has better compatibility with combined medications and can avoid obvious effects on cognitive function. Compared with levetiracetam, brivaracetam has approximately 20 times higher affinity for SV2A, which means it can achieve stronger neurostabilizing effects at lower doses and reduce the incidence of adverse reactions.

In terms of clinical application, Brivaracetam is used to treat partial-onset epilepsy in adults and adolescents over 16 years old. Whether as a single drug or in combination therapy, it has shown significant anti-seizure effects. Overseas research shows that Brivaracetam has a rapid onset of action, and the frequency of seizures in some patients is significantly reduced within a short period of time after taking the drug. Because it does not rely on the metabolism of the liver's CYP system, it has fewer drug interactions and can be used in combination with other antiepileptic drugs, antidepressants or antipsychotics without affecting its efficacy. This feature is particularly important for epilepsy patients who take long-term medication, as they often require a combination of multiple drugs to control different types of seizures.

Brivaracetam also received high ratings for safety and tolerability. It is well tolerated by most patients, and common minor adverse reactions include drowsiness, dizziness, and fatigue, which usually diminish over time. Compared with levetiracetam, brivaracetam was associated with lower rates of mood disturbance, irritability, or aggressive behavior, indicating that it has less impact on mood-related neurotransmitter pathways. This advantage makes it one of the first-choice anti-epileptic drugs for patients who are emotionally sensitive or prone to depression. For patients with normal liver function, the metabolism of the drug is mainly completed through the hydrolysis pathway, and patients with mildly impaired renal function do not need to adjust the dosage, showing high pharmacokinetic stability.

Globally, brivaracetam has been widely included in multinational epilepsy treatment guidelines and is considered one of the important drugs for controlling partial seizures. Especially in patients who are resistant or intolerant to levetiracetam, the replacement treatment effect of brivaracetam is significant. Due to its optimized molecular structure, it can achieve the desired therapeutic effect with a smaller dose, reducing drug accumulation and the risk of side effects.

Reference materials:https://www.briviact.com/